Relevant bibliographies by topics / Key Words: Drug Eluting Stent (DES)

Contents

  1. Journal articles
  2. Reports

Academic literature on the topic 'Key Words: Drug Eluting Stent (DES)'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Key Words: Drug Eluting Stent (DES).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Key Words: Drug Eluting Stent (DES)"

1

Tinanda Tarigan, Daniel Sukmadja, Kaka Citta Prasiddha, and Rizkan Triatmaja. "Comparative efficacy of drug-eluting balloon and drug-eluting stent for treatment of in-stent restenosis: a systematic review and meta-analysis." Journal of the Pakistan Medical Association 74, no. 6 (Supple) (2024): S51—S56. http://dx.doi.org/10.47391/jpma.s6-acsa-09.

Full text
Abstract:
Objective: To compare the efficacy of drug-eluting stents and drug-eluting balloons in treating in-stent restenosis. Method: The systematic review was conducted from January to February 2022, and comprised literature search on PubMed, ProQuest, Cochrane Library and Google Scholar databases with relevant key words to locate randomised controlled trials and observational studies published between 2000 and 2022 that compared drugeluting balloons and drug-eluting stents in the treatment of in-stent restenosis. The outcomes were all-cause death, cardiovascular death, major adverse cardiovascular ev
APA, Harvard, Vancouver, ISO, and other styles
2

Chong, Eric, Kian Keong Poh, Shen Liang, Xu Min Hou, and Huay Cheem Tan. "Eighteen-Month Clinical Safety and Efficacy Outcomes of Sirolimus-, Paclitaxel and Zotarolimus-drug Eluting Stents in Diabetic Patients Undergoing Percutaneous Coronary Intervention for Complex Coronary Artery Stenosis." Annals of the Academy of Medicine, Singapore 39, no. 5 (2010): 381–84. http://dx.doi.org/10.47102/annals-acadmedsg.v39n5p381.

Full text
Abstract:
Introduction: This was a single centre registry study on clinical efficacy and safety of drug-eluting stent (DES) in diabetic patients undergoing percutaneous coronary intervention (PCI) for complex coronary lesions. Materials and Methods: A total of 288 diabetic patients who underwent elective PCI between September 2003 and June 2006 in our centre were enrolled and followed-up for 18 months. Among them, 79 (27.4%) patients received sirolimus-eluting stent (SES), 138 (47.9%) paclitaxel-eluting stent (PES) and 71 (24.7%) zotarolimus-eluting stent (ZES). The endpoints were major adverse cardiac
APA, Harvard, Vancouver, ISO, and other styles
3

Chandwani, Prakash, Bhavesh Meel, Rahul Singhal, et al. "Three-Year Outcomes of Biodegradable Polymer-Coated Ultra-Thin (60 µm) Sirolimus-Eluting Stents in Real-World Clinical Practice." Annals of the Academy of Medicine, Singapore 48, no. 5 (2019): 150–55. http://dx.doi.org/10.47102/annals-acadmedsg.v48n5p150.

Full text
Abstract:
Introduction: Although drug-eluting stents (DES) have outclassed the use of bare metal stents, the safety and efficacy of DES at long-term follow-up has still been conflicting because of increased occurrence of late or very late restenosis and stent thrombosis after DES implantation. Hence, the present study was aimed to evaluate the 3-year safety and clinical performance of biodegradable polymer-coated ultra-thin (60 μm) sirolimus-eluting stent (SES) in real-world patients with coronary artery disease (CAD). Materials and Methods: This was a physician-initiated, retrospective, single-centre,
APA, Harvard, Vancouver, ISO, and other styles
4

Chetan, R. Patela* Mandev B. Patelb. "A study to compare Major Adverse Cardiac Event in patient undergoing PCI with Drug Eluting Stents Vs Bare Metal Stents." Journal of Pharma Research 1, no. 1 (2012): 12–15. https://doi.org/10.5281/zenodo.1098639.

Full text
Abstract:
<strong><em>ABSTRACT</em></strong> <em>This study compared Major Adverse Cardiac Event in patient with Acute Coronary Syndromes undergoing PCI with Drug Eluting Stents Vs Bare Metal Stents. A retrospective, observational study was carried out in an inpatient setting of the private tertiary care hospital. Patients with &gt;18 years, diagnosed for Acute Coronary Syndromes (ACS), required intervention in coronary artery with implantation of Drug Eluting Stents (DES) or Bare Metal Stents (BMS) were recruited in the study. The data had been collected from file or database of the hospital. All subje
APA, Harvard, Vancouver, ISO, and other styles
5

Liang, Michael, The Vun Liew, Aniket Puri, Lauren Hyde, and Gerard Devlin. "Medium to Long-Term Clinical Outcomes with Everolimus-Eluting Stents in Real-Life Percutaneous Coronary Intervention." Annals of the Academy of Medicine, Singapore 41, no. 6 (2012): 252–57. http://dx.doi.org/10.47102/annals-acadmedsg.v41n6p252.

Full text
Abstract:
Introduction: Everolimus eluting stents (EES) have demonstrated excellent re-stenosis and thrombosis rates in a number of randomised controlled trials. This study reported the real world experience in a single tertiary centre with EES in predominantly acute coronary syndrome (ACS) patients and compared the outcomes in small and large vessels. We measured the medium to long-term major adverse cardiovascular events (MACE) defi ned as all-cause mortality, myocardial infarction (MI) and target vessel revascularisation (TVR) and stent thrombosis. Materials and Methods: All consecutive patients unde
APA, Harvard, Vancouver, ISO, and other styles
6

Yaneza, Liberty O., and Leah T. Verdillo. "Comparison of Drug Eluting Stents Versus Bare Metal Stents in Femoropopliteal Artery Occlusive Disease: A Systematic Review and Meta-analysis." Philippine Journal of Cardiology 40, no. 1 (2012): 13–21. http://dx.doi.org/10.69944/pjc.417b9d1162.

Full text
Abstract:
OBJECTIVES: To compare the angiographic and clinical outcomes in patients who have undergone peripheral artery intervention using either drug eluting stents (DES) or bare metal stents (BMS). METHODS: A meta-analysis of randomized studies that compare DES and BMS in patients with femoropopliteal occlusive artery disease. RESULTS: Five clinical trials met the inclusion criteria. Results showed that using DES yielded a higher arterial patency rate (RR 1.41; 95% CI 1.23-1.61), reduced restenosis rate (RR 0.46; 95% CI 0.33-0.63), and had a lesser tendency for repeat revascularization (RR 0.29; 95%
APA, Harvard, Vancouver, ISO, and other styles
7

Jibran, Rushd, Junaid Alam Khan, and Angela Hoye. "Gender Disparity in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes – Does it Still Exist in Contemporary Practice?" Annals of the Academy of Medicine, Singapore 39, no. 3 (2010): 173–78. http://dx.doi.org/10.47102/annals-acadmedsg.v39n3p173.

Full text
Abstract:
Introduction: Prior studies have demonstrated evidence of a disparity in the treatment and outcome of male compared to female patients undergoing percutaneous coronary intervention (PCI). Materials and Methods: From a dedicated database, we retrospectively analysed all consecutive patients with acute coronary syndrome (ACS) admitted to our institution for PCI in 2008. Baseline and procedural characteristics as well as complications were then evaluated for male patients (n = 331) as compared with female patients (n = 137). Results: Women were noted to be older at the time of presentation (66.1
APA, Harvard, Vancouver, ISO, and other styles
8

Mahmoud, Elsayed Abdelatif, Alakabawy Hazem, Fawzy Mohamed, and Fahmy Abdelraouf. "Comparison between coronary artery bypass surgery and percutaneous coronary intervention with drug-eluting stents for Egyptian diabetic patients with Multivessel disease." Biolife 5, no. 3 (2022): 295–302. https://doi.org/10.5281/zenodo.7364728.

Full text
Abstract:
<strong>ABSTRACT</strong> <strong><em>Background: </em></strong>With the advances in the interventional field, the usage of DES make the choice of revascularization in diabetic patients with MVD controversial. <strong><em>Methods: </em></strong>We assigned patients with diabetes and MVD to undergo either PCI with DES or CABG. The patients were followed up for 12 months. The primary outcome was a composite of death, MI, repeated revascularization or stroke. <strong><em>Results: </em></strong>The study was conducted on 225 patients (116 patients randomly assigned to the PCI group and 109 randoml
APA, Harvard, Vancouver, ISO, and other styles
9

Hsiao, Hao Ming, Chun Ting Yeh, Tsung Yuan Wu, Li Wei Wu, Bor Hann Huang, and Hsiao Nan Yang. "Design and Manufacturing of Drug Eluting Depot Stents with Micro-Sized Drug Reservoirs." Applied Mechanics and Materials 479-480 (December 2013): 225–29. http://dx.doi.org/10.4028/www.scientific.net/amm.479-480.225.

Full text
Abstract:
The effects of micro-sized through-hole drug reservoirs on several key clinical attributes of the drug eluting depot stent were investigated. Finite element models were developed to predict the mechanical integrity of a balloon-expandable stent at various stages such as manufacturing and deployment, as well as the stent radial strength and fatigue life. Results show that (1) creating drug reservoirs on a stent could impact the stent fatigue resistance to certain degrees, and (2) drug reservoirs on the stent crowns led to much greater loss in all key clinical attributes than reservoirs on other
APA, Harvard, Vancouver, ISO, and other styles
10

Allocco, Dominic J., Mary V. Jacoski, Barbara Huibregtse, Tim Mickley, and Keith D. Dawkins. "Platinum Chromium Stent Series – The TAXUS™ Element™ (ION™), PROMUS Element™ and OMEGA™ Stents." Interventional Cardiology Review 6, no. 2 (2011): 134. http://dx.doi.org/10.15420/icr.2011.6.2.134.

Full text
Abstract:
Advances in drug-eluting stent technology have continued to improve clinical outcomes for patients undergoing percutaneous coronary intervention (PCI). The Boston Scientific stent platform has evolved from the 316L stainless steel Express™ stent, to the 316L stainless steel Liberté™ stent, to the cobalt–chromium PROMUS™ stent and, finally, to the platinum–chromium (PtCr) stent series. The PtCr platform, which uses the Element architecture, is designed to have improved deliverability, radiopacity, radial strength and recoil resistance compared with existing stainless steel or cobalt–chromium st
APA, Harvard, Vancouver, ISO, and other styles
More sources

Reports on the topic "Key Words: Drug Eluting Stent (DES)"

1

Wei, Dongmei, Yang Sun, and Rongtao Chen. Risk prediction model for ISR after coronary stenting-a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.4.0014.

Full text
Abstract:
Review question / Objective: The efficacy of risk prediction model for ISR. Condition being studied: Coronary heart disease (CHD), with high morbidity and high mortality rate, is still a serious public health concern around the world. PCI is fast becoming a key instrument in revascularization for patients with CHD, as well as an important technology in the management of CHD patients.1 Although the clinical application of coronary stents brought about a dramatic improvement in patients’ clinical and procedural outcomes, the mid-and long-term outcome of stent implantation remains significantly h
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Key Words: Drug Eluting Stent (DES)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography